This clinical trial seeks to fill a global gap in the treatment of uncomplicated vivax malaria: to evaluate the safety and tolerability of short and long-term primaquine treatment regimens for uncomplicated vivax malaria in children. Thus, it hopes to provide a clinical and laboratory description of the main adverse events related to primaquine treatment in children, whether long (14 days) or short (7 days). This will inform safe and tolerable treatment for thousands of children who suffer from successive vivax malaria infections and are cared for by the Brazilian public health service and will help prevent complications after treatment begins.
Display Title (Formatted)
Phase II Study to Evaluate Primaquine Safety and Tolerability for Radical Cure of Uncomplicated Plasmodium vivax Malaria in Children (CHILDPRIM Study)
Grant ID
442917/2019-8
Show on Hub
On
Show on Spoke
On
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
805600.00
Funding Currency
BRL
Exchange Rate (at time of payment)
0.2392900000
Funding Amount (in USD)
192772.00
Project Type
Project Primary Sector
Funding Date Range
-
Funding Total (In US dollars)
192772.02
Co-Funded
False